Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02108041
Other study ID # 999914075
Secondary ID 14-HG-N075
Status Completed
Phase
First received
Last updated
Est. completion date October 8, 2020

Study information

Verified date January 8, 2024
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: -How people respond to drugs depends in part on their genes. For some drugs, doctors can use an individuals genetic background to help in dosing the drug. Researchers want to know how doctors incorporate personalized or genomic medicine into clinical practice. Objective: -To study how physicians make personalized treatment decisions Eligibility: -Healthy adult primary care physicians who are internal (or family) medicine residents. Design: - Participants will complete a screening form. - Participants will put on a headset, called a head-mounted display, showing a virtual reality environment. - The environment will contain an exam room and the virtual patient. - After interacting with the virtual patient, participants will complete a series of survey measures. - Participation will last for about 60 minutes. The virtual patient interaction and follow-up questions will be audio taped.


Description:

This study will examine factors related to primary care physicians clinical decision-making. Using a virtual clinical interaction experiment, we aim to better understand physicians decision-making processes and to explore their communication behaviors toward patients in the clinical encounter. Physician participants will enter a virtual exam room where they will be asked to respond to a virtual patient, acting as her primary care physician in a follow-up visit to evaluate her for depression. Various aspects of physician communication in the virtual clinic and self-report measures related to decision-making will be analyzed.


Recruitment information / eligibility

Status Completed
Enrollment 196
Est. completion date October 8, 2020
Est. primary completion date October 8, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility - INCLUSION CRITERIA: - All physicians will be healthy adult volunteers who are medical residents in the internal medicine specialty. EXCLUSION CRITERIA: 1. persons with seizure or vestibular disorders; 2. persons who are highly prone to motion sickness; 3. those without normal or normal to corrected vision or hearing; 4. all current and past employees and contractors of NHGRI; and 5. persons who have received information about the study purpose or procedure from a past participant. NHGRI employees are excluded for this protocol because they are likely to have specialized genomic knowledge and may think differently about genomics in the clinical interaction.

Study Design


Locations

Country Name City State
United States Johns Hopkins School of Medicine Baltimore Maryland
United States Harvard School of Public Health Boston Massachusetts
United States University of Oregon Eugene Oregon
United States Michigan State University Flint Michigan
United States Columbia University New York New York

Sponsors (1)

Lead Sponsor Collaborator
National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Armstrong K. Genomics and health care disparities: the role of statistical discrimination. JAMA. 2012 Nov 21;308(19):1979-80. doi: 10.1001/2012.jama.10820. No abstract available. — View Citation

Green AR, Carney DR, Pallin DJ, Ngo LH, Raymond KL, Iezzoni LI, Banaji MR. Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Gen Intern Med. 2007 Sep;22(9):1231-8. doi: 10.1007/s11606-007-0258-5. Epub 2007 Jun 27. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial/ethnic and SES backgrounds To explore how physicians use genetic testing for anticoagulant (warfarin) dosage in patients of different racial /ethnic and SES backgrounds Outcome measurements are assessed on the same date of the study visit.
See also
  Status Clinical Trial Phase
Recruiting NCT05003843 - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis N/A
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters N/A
Completed NCT03420625 - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02555111 - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Phase 3
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT01975090 - The SENTRY Clinical Study N/A
Completed NCT02037607 - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Completed NCT00264277 - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Phase 4
Completed NCT00365950 - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Phase 4
Completed NCT00182403 - Fixed Dose Heparin Study Phase 3
Completed NCT03682419 - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) N/A
Not yet recruiting NCT04981327 - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis Phase 3
Recruiting NCT03240120 - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism Phase 3